Latest:
Dr. Lilenbaum on the Rise of Immunotherapy in NSCLC
Rogerio C. Lilenbaum, MD, discusses the rise of immunotherapy in non–small cell lung cancer.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Roisin E. O’Cearbhaill, MD
Latest:
HIPEC for Ovarian Cancer: An Exciting Locoregional Strategy
Approximately 22,000 women will be diagnosed with epithelial ovarian cancer (EOC) in the United States in 2014, making it the nation's second most common gynecologic malignancy.1 The cancer, which often presents at an advanced stage, causes more deaths than any other type of gynecologic malignancy.
Ronald de Wit, MD, PhD
Latest:
Dr. de Wit on the AEs With Cabazitaxel in the CARD Trial in mCRPC
Ronald de Wit, MD, PhD, group leader, Experimental Systematic Therapy of Urogenital Cancers program, Erasmus MC Cancer Institute, Rotterdam, Netherlands, discusses the adverse events (AEs) with cabazitaxel (Jevtana) in the phase III CARD trial in patients with metastatic castration-resistant prostate cancer (mCRPC).
Ronan Flippot, MD, MSc
Latest:
New Perioperative Strategies Emerge for High-Risk, Resectable RCC
The current management of metastatic renal cell carcinoma reflects the progress of medical oncology throughout the past several decades. The standard of care has evolved from cytokine-based therapies to targeted molecular therapies and immune checkpoint inhibitor–based strategies.
Ronan J. Kelly, MD, MBA, FASCO
Ronan J. Kelly, MD, MBA, FASCO, is director of the Charles A. Sammons Cancer Center and chief science officer at Baylor University Medical Center; the W.W. Caruth Jr. Endowed Chair of Immunology at Baylor University Medical Center; chief of Oncology Baylor Scott & White Health System; founder and medical director of the Texas Cancer Interception Institute; a clinical professor at the Texas A&M University College of Medicine; an adjunct associate professor of oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; and a professor in the Clinical Sciences Division at the Translational Genomics Research Institute
Latest:
Multidisciplinary Collaboration Gives Forward Momentum to HER2 IHC Testing in NSCLC: With Ronan J. Kelly, MD, MBA, FASCO; and Michelle Shiller, DO, AP/CP, MGP
Drs Kelly and Shiller discuss the importance of performing IHC testing for HER2 in NSCLC and recommendations for IHC testing implementation in practice.
Ronan T. Swords, MD, PhD, FRCPI, FRCPath
Latest:
Dr. Swords on Anti-Tumor Effects of IMG-98 in AML
Ronan T. Swords, MD, discusses preclinical findings demonstrating that the small-molecule inhibitor IMG-98 effectively augments pro-differentiation effects of all-trans-retinoic acid–based therapies in acute myeloid leukemia.